Fmr LLC cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 45.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,071,427 shares of the company’s stock after selling 894,233 shares during the period. Fmr LLC owned 0.10% of Eli Lilly and worth $88,178,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Eli Lilly and by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock valued at $5,778,109,000 after purchasing an additional 1,610,885 shares during the period. D.A. Davidson & CO. lifted its position in Eli Lilly and by 1.2% during the 2nd quarter. D.A. Davidson & CO. now owns 35,908 shares of the company’s stock valued at $2,955,000 after purchasing an additional 411 shares during the period. Pinebridge Investments L.P. acquired a new position in Eli Lilly and during the 2nd quarter valued at about $7,402,000. Van ECK Associates Corp lifted its position in Eli Lilly and by 1.0% during the 2nd quarter. Van ECK Associates Corp now owns 525,029 shares of the company’s stock valued at $43,210,000 after purchasing an additional 5,190 shares during the period. Finally, Quantitative Investment Management LLC lifted its position in Eli Lilly and by 12.9% during the 2nd quarter. Quantitative Investment Management LLC now owns 75,200 shares of the company’s stock valued at $6,188,000 after purchasing an additional 8,600 shares during the period. Institutional investors own 75.48% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Fmr LLC Cuts Holdings in Eli Lilly and Company (LLY)” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://ledgergazette.com/2017/11/13/fmr-llc-cuts-holdings-in-eli-lilly-and-company-lly.html.
A number of brokerages recently weighed in on LLY. Morgan Stanley set a $86.00 price target on shares of Eli Lilly and and gave the company a “hold” rating in a research report on Friday, October 6th. Leerink Swann increased their price target on shares of Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. BMO Capital Markets set a $73.00 price target on shares of Eli Lilly and and gave the company a “sell” rating in a research report on Tuesday, October 24th. Credit Suisse Group downgraded shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and increased their price target for the company from $84.23 to $88.00 in a research report on Tuesday, October 10th. Finally, Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $95.00 price target (up from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $89.76.
Eli Lilly and Company (NYSE:LLY) opened at $83.29 on Monday. The firm has a market cap of $91,710.21, a P/E ratio of 20.36, a PEG ratio of 1.83 and a beta of 0.34. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $89.09. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period last year, the business earned $0.88 EPS. equities research analysts predict that Eli Lilly and Company will post 4.22 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. The ex-dividend date is Tuesday, November 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.50%. Eli Lilly and’s dividend payout ratio is currently 98.58%.
In other news, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the transaction, the insider now directly owns 123,865,804 shares of the company’s stock, valued at approximately $10,040,562,072.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 770,000 shares of company stock valued at $64,669,850 over the last ninety days. Company insiders own 0.20% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.